ClinicalTrials.gg
CompletedNCT00262249Updated Jan 18, 2017

Effect of Growth Hormone in Children With Growth Hormone Deficiency

A Phase 3 interventional study of somatropin in Growth Hormone Disorder, Growth Hormone Deficiency in Children and Growth Disorder, sponsored by Novo Nordisk A/S. Completed at 40 sites in United States. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
3 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies in Growth Disorders with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Growth Disorders · United States.

Enrollment
4th of 17
173 · median 50
Started
2000
the only one that year
Phase 3
4 of 25
1 open now
Registered
7th of 25
by date
Lead sponsor
4 of 25
Novo Nordisk A/S

Among the 25 studies in Growth Disorders with a site in United States, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2000, is one of 4 in phase 3, and was the 7th registered.

Growth Disorders

227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.

Browse Growth Disorders studies →

Open to participants now

4 of the 25 studies in Growth Disorders with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Growth Disorders studies recruiting now, 3 (17%) set no upper age limit and 13 (72%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 3 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Growth Disorders with a site in United States, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.

03

Conditions studied

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Growth Disorder
  • Idiopathic Short Stature

Browse trials for

04

Who can participate

Ages eligible
3 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically suspected GHD
  • Height \< -2.0 SDS
  • Serum IGF-I less than or equal to -1.0 SDS
  • Bone age less than or equal to 9 years for boys and less than or equal to 7 years for girls.
  • Puberty Tanner Stage I

Exclusion criteria

Exclusion Criteria:

  • Previous use of growth hormone
  • Growth retardation attributable to causes other than GHD (e.g. inborn errors of metabolism, primary bone disease, chromosomal disorders, etc.)
  • Intrauterine growth retardation: birth weight \< 3rd percentile.
  • Administration of other growth-altering medications.
  • Evidence of any or intracranial tumors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
173 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in height standard deviation score

    Time frame: 24 month

Secondary outcomes

  1. IGF-I

  2. IGFBP-3

  3. free IGF-I

07

Study locations

40 sites
  • Novo Nordisk Investigational Site
    Los Angeles, California 90027, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90095, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95817, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92093, United States
  • Novo Nordisk Investigational Site
    Stanford, California 94305-5208, United States
  • Novo Nordisk Investigational Site
    New Haven, Connecticut 06520, United States
  • Novo Nordisk Investigational Site
    Gainesville, Florida 32608, United States
  • Novo Nordisk Investigational Site
    St. Petersburg, Florida 33701, United States
  • Novo Nordisk Investigational Site
    Tallahassee, Florida 32308, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46202, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    Shreveport, Louisiana 71130-3932, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21287, United States
  • Novo Nordisk Investigational Site
    Springfield, Massachusetts 01107, United States
  • Novo Nordisk Investigational Site
    Worcester, Massachusetts 01655, United States
  • Novo Nordisk Investigational Site
    Kalamazoo, Michigan 49008, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64108, United States
  • Novo Nordisk Investigational Site
    Morristown, New Jersey 07962, United States
  • Novo Nordisk Investigational Site
    Bronx, New York 10467, United States
  • Novo Nordisk Investigational Site
    Brooklyn, New York 11219, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14222, United States
  • Novo Nordisk Investigational Site
    New Hyde Park, New York 11042, United States
  • Novo Nordisk Investigational Site
    New York, New York 10029, United States
  • Novo Nordisk Investigational Site
    Stony Brook, New York 11794, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45229, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44106, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44195, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43205, United States
  • Novo Nordisk Investigational Site
    Portland, Oregon 97239, United States
  • Novo Nordisk Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29425, United States
  • Novo Nordisk Investigational Site
    Columbia, South Carolina 29203, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38103, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78284, United States
  • Novo Nordisk Investigational Site
    Seattle, Washington 98105, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53226-0509, United States
08

References and documents

Publications

  • Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG; American Norditropin Study Group. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007 Jul;92(7):2480-6. doi: 10.1210/jc.2007-0204. Epub 2007 Mar 13. PubMed 17356043 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2000, a primary completion of May 2004 and a completion of May 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2005
First posted
Dec 6, 2005
Start
Aug 2000
Primary completionActual
May 2004
CompletionActual
May 2004
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00262249
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 6, 2005
Start date
Aug 2000
Primary completion
May 2004
Completion
May 2004
Last update
Jan 18, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion